Revolution Medicines (RVMD) FCF Margin (2019 - 2023)

Revolution Medicines has reported FCF Margin for 5 years, with the latest figure at 16145.15% in Q4 2023.

• On a quarterly basis, FCF Margin fell 1572333.0% year-over-year to 16145.15% in Q4 2023; TTM through Sep 2024 was 73858.36%, a 7269981.0% decrease from a year earlier, with the FY2023 full-year figure at 3094.14%, down 242931.0% from the prior year.
• FCF Margin was 16145.15% for Q4 2023 at Revolution Medicines, down from 1784.52% in the prior quarter.
• The five-year high for FCF Margin was 98.33% in Q1 2019, with the low at 16145.15% in Q4 2023.
• Average FCF Margin over 5 years is 1489.16%, with a median of 406.91% recorded in 2021.
• The sharpest annual moves came in 2022 and 2023: FCF Margin surged 171773 bps in 2022, then slumped 1572333 bps in 2023.
• Over 5 years, FCF Margin stood at 100.61% in 2019, then sank by 198 bps to 299.43% in 2020, then plunged by 43 bps to 427.57% in 2021, then gained by 1 bps to 421.81% in 2022, then slumped by 3728 bps to 16145.15% in 2023.
• The last three FCF Margin figures came in at 16145.15% (Q4 2023), 1784.52% (Q2 2023), and 914.59% (Q1 2023), per Business Quant data.